Table 2.
Mutation Frequencies in TCC and TCGA
| Gene | TCC Extended | TCGA | combined | ||||||
|---|---|---|---|---|---|---|---|---|---|
| younger n=51 |
older n=195 |
P-value | younger n=29 |
older n=220 |
P-value | younger n=80 |
older n=415 |
P-value | |
| APC | 60.8% | 73.8% | 0.66 | 51.7% | 73.6% | 0.027 | 57.5% | 73.7% | 0.0046 |
|
BRAF (V600E) |
2.0% | 5.6% | 0.47 | 0% | 8.2% | 0.24 | 1.3% | 7.0% | 0.043 |
| FBXW7 | 27.5% | 9.7% | 0.0022 | 20.7% | 11.4% | 0.22 | 25.0% | 10.6% | 0.0016 |
| KRAS | 43.1% | 46.1% | 0.33 | 41.4% | 33.6% | 0.41 | 42.5% | 39.5% | 0.62 |
|
POLE proofre ading |
9.8% | 1.0% | 0.0048 | 10.3% | 0.91% | 0.012 | 10% | 0.96% | 9.7e–5 |
| TP53 | 64.7% | 61.5% | 0.42 | 51.7% | 52.7% | 1 | 60% | 56.9% | 0.62 |
TCC: Total Cancer Care; TCGA: The Cancer Genome Atlas; APC: Adenomatous polyposis coli gene; BRAF: Proto-oncogene B-Raf; FBXW7: F-box/WD repeat containing protein 7; KRAS: Kirsten rat sarcoma viral oncogene homolog; POLE: Polymerase epsilon catalytic subunit; TP53: Tumor protein p53